To include your compound in the COVID-19 Resource Center, submit it here.

$145M raise positions Rallybio to bring first rare disease program into clinic

Pivotal bioVenture leads megaround for biotech helmed by Alexion veterans

With its series A funds deployed to acquire three rare disease programs, Rallybio has raised a $145 million series B led by Pivotal bioVenture Partners to bring the first of those candidates into the clinic next half, and to continue its in-licensing spree.

Fellow new investors including Viking Global Investors, TPG Capital’s The Rise Fund, F-Prime Capital, funds managed by

Read the full 593 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE